Dermatology (36 companies · 19 conditions)

Conditions

Atopic Dermatitis 14 Hidradenitis Suppurativa 8 Rare Psoriasis 7 Alopecia Areata 3 Acne 2 Netherton Syndrome 2 Rare Onychomycosis 2 Recessive Dystrophic Epidermolysis Bullosa 2 Rare Androgenetic Alopecia 1 Common Wart 1 Junctional Epidermolysis Bullosa 1 Rare Lichen Planus 1 Lymphatic Malformation 1 Rare Molluscum Contagiosum 1 Peeling Skin Syndrome 1 Rare Pemphigus 1 Rare PIK3CA-Related Overgrowth Spectrum 1 Rare Rosacea 1 Vitiligo 1

Companies

Ticker	Company	Therapeutic areas	In Dermatology	Lead stage	Mkt cap	Programs
AARD	Aardvark Therapeutics	DermatologyMetabolic+1 Rare	1	Phase 3	$25.6M	3
ABSI	Absci	DermatologyGI/Hepatology+1	1	Phase 1	$1.75B	6
ACRS	Aclaris Therapeutics	DermatologyGI/Hepatology+1 Rare	5	Phase 2	$619M	8
ALDX	Aldeyra Therapeutics	DermatologyOncology+1	1	NDA Submitted	$38.3M	5
ANAB	AnaptysBio	DermatologyGI/Hepatology+2 Rare	1	Approved	$1.39B	9
APGE	Apogee Therapeutics	DermatologyGI/Hepatology+1 Rare	3	Phase 2	—	9
RCUS	Arcus Biosciences	DermatologyImmunology+1	1	Phase 3	$2.63B	8
BCRX	Biocryst Pharmaceuticals	DermatologyImmunology+1 Rare	1	Approved	$1.98B	4
CABA	Cabaletta Bio	DermatologyImmunology+2 Rare	1	Phase 2	$280M	8
CLDX	Celldex Therapeutics	DermatologyImmunology+1	1	Phase 3	$2.35B	9
CRVS	Corvus Pharmaceuticals	DermatologyOncology+1 Rare	2	Phase 3	$889M	7
ELOX	Eloxx Pharmaceuticals	DermatologyRenal Rare	2	Phase 2	$50.2M	4
ENTA	Enanta Pharmaceuticals	DermatologyImmunology+1	1	Approved	$320M	7
EVMN	Evommune	DermatologyImmunology+1	2	Phase 2	$241M	6
FBRX	Forte Biosciences	DermatologyGI/Hepatology	2	Phase 2	—	3
FBIO	Fortress Biotech	DermatologyHematology+3 Rare	3	Approved	$61.7M	12
IMCR	Immunocore	DermatologyInfectious Disease+2	1	Approved	$1.60B	15
INMB	Inmune Bio	Dermatology Rare	1	Phase 3	$35.0M	1
KYMR	Kymera Therapeutics	DermatologyImmunology+1 Rare	2	Phase 2	$11.2B	5
GLUE	Monte Rosa Therapeutics	CardiovascularDermatology+3 Rare	1	Phase 2	$903M	7
MLTX	MoonLake Immunotherapeutics	DermatologyImmunology Rare	1	NDA Submitted	$981M	4
NKTR	Nektar Therapeutics	DermatologyImmunology+2	2	Phase 3	$1.27B	11
ORKA	Oruka Therapeutics	DermatologyImmunology Rare	4	Phase 2	$6.81B	7
PTGX	Protagonist Therapeutics	DermatologyHematology+2 Rare	2	Approved	$8.62B	12
TARA	Protara Therapeutics	DermatologyMetabolic+1 Rare	1	Phase 3	$142M	3
QTTB	Q32 Bio	Dermatology	1	Phase 2	$277M	3
QNRX	Quoin Pharmaceuticals	DermatologyImmunology Rare	2	Phase 2	$257M	4
RLAY	Relay Therapeutics	DermatologyOncology Rare	1	Approved	$4.11B	4
RVPH	Reviva Pharmaceuticals	CardiovascularDermatology+2 Rare	1	Phase 3	$4.8M	10
SGMT	Sagimet Biosciences	DermatologyMetabolic	2	Phase 3	$698M	3
SYRE	Spyre Therapeutics	DermatologyImmunology Rare	1	Phase 2	$9.86B	10
TTRX	Turn Therapeutics	DermatologyInfectious Disease Rare	3	Phase 2	$282M	4
VNDA	Vanda Pharmaceuticals	CardiovascularDermatology+6 Rare	4	Approved	$231M	27
VRCA	Verrica Pharmaceuticals	DermatologyOncology	2	Approved	$54.8M	3
ZBIO	Zenas BioPharma	DermatologyImmunology+2 Rare	1	NDA Submitted	$1.92B	11
ZURA	Zura Bio	DermatologyImmunology Rare	2	Phase 2	$394M	5